EVM
ITCI

Eaton Vance Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Eaton Vance Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-500
Closed -$26K – 2779
2021
Q4 		$26K Hold
500
– – ﹤0.01% 2334
2021
Q3 		$0 Hold
500
– – ﹤0.01% 2769
2021
Q2 		$20K Sell
500
-1,161
-70% -$42.9K ﹤0.01% 2427
2021
Q1 		$56K Buy
+1,661
New +$57.6K ﹤0.01% 1769

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Eaton Vance Management's ITCI Position: Q1 2022 in Review

Eaton Vance Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2022, closing a stake of 500 shares — an estimated $26K sold.

Eaton Vance Management first reported a position in ITCI in Q1 2021 and held it in 4 quarters. The position peaked at $56K in Q1 2021. 241 funds tracked by Wall St. Rank hold ITCI as of Q1 2022.

  • Eaton Vance Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2022 after selling out during the quarter.
  • Eaton Vance Management sold 500 Intra-Cellular Therapies Inc. shares in Q1 2022, an estimated $26K.
  • Eaton Vance Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2021 and held it in 4 quarters.
  • Eaton Vance Management's Intra-Cellular Therapies Inc. position peaked at $56K in Q1 2021.
  • 241 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2022.

Based on Eaton Vance Management's 13F filing for Q1 2022, filed 16 May 2022.